Predictive Oncology (POAI) Competitors

Predictive Oncology (NASDAQ:POAI) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.

Which has preferable valuation and earnings, POAI or DRIO?

Predictive Oncology has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.73M	4.96	-$13.98M	-$3.05	-0.31
DarioHealth	$28.03M	1.06	-$59.43M	-$0.56	-1.19

Which has more risk and volatility, POAI or DRIO?

Predictive Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Does the media favor POAI or DRIO?

In the previous week, Predictive Oncology had 1 more articles in the media than DarioHealth. MarketBeat recorded 3 mentions for Predictive Oncology and 2 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.93 beat Predictive Oncology's score of 0.72 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DarioHealth	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in POAI or DRIO?

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 3.4% of Predictive Oncology shares are owned by insiders. Comparatively, 11.2% of DarioHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts recommend POAI or DRIO?

Predictive Oncology currently has a consensus target price of $3.00, suggesting a potential upside of 212.50%. DarioHealth has a consensus target price of $2.00, suggesting a potential upside of 200.30%. Given Predictive Oncology's higher probable upside, equities research analysts plainly believe Predictive Oncology is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DarioHealth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Is POAI or DRIO more profitable?

DarioHealth has a net margin of -205.62% compared to Predictive Oncology's net margin of -1,012.32%. DarioHealth's return on equity of -72.16% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-1,012.32%	-286.30%	-122.11%
DarioHealth	-205.62%	-72.16%	-40.74%

Does the MarketBeat Community favor POAI or DRIO?

DarioHealth received 91 more outperform votes than Predictive Oncology when rated by MarketBeat users. Likewise, 66.85% of users gave DarioHealth an outperform vote while only 64.22% of users gave Predictive Oncology an outperform vote.

Company	Underperform	Outperform
Predictive Oncology	Outperform Votes 149 64.22%	Underperform Votes 83 35.78%
DarioHealth	Outperform Votes 240 66.85%	Underperform Votes 119 33.15%

Summary

DarioHealth beats Predictive Oncology on 13 of the 18 factors compared between the two stocks.